Navigation Links
PRA International Hosts Audio Conference on CV Drug Development
Date:8/16/2010

RALEIGH, N.C., Aug. 16 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

Dr. Kirchengast will discuss ways to prevent some of the expensive failures that pharmaceutical companies experience during late-stage CV drug development. The conference will review predictive pre-clinical models, innovative proof-of-concept designs in Phase IIa, cooperation among sponsors and regulatory agencies, and simpler protocols with similar endpoints throughout Phases II and III.

PRA's therapeutic expert in CV disease, Dr. Kirchengast has 30 years of experience in CV research and development, including interactions with multiple authorities. His wide range of development experience encompasses antiarrhythmics, antithrombotics, antihypertensives, antihyperlipidemics, heart failure therapeutics, and vascularly active and cardioprotective drugs.

PRA's Scientific Affairs group consists of strategic drug development professionals with expertise in medical informatics and investigator relations as well as therapeutic expertise in cardiovascular, oncology/hematology, infectious diseases, neurosciences, pediatrics, and respiratory medicine. The group combines in-house scientific expertise with hands-on pharmaceutical industry experience, guiding the development of drugs and biologics from the late preclinical phase to the marketing stage across PRA's core therapeutic areas.

For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email endpoints@praintl.com. The registration deadline is Monday, 23 August 2010.

About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dyadic International Reports 2010 Second Quarter Financial Results
2. Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
3. Chindex International to Report First Quarter 2011 Financial Results
4. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
5. Airline Passenger Experience Association Teams Up With ORBIS International in Their Fight Against Avoidable Blindness
6. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
7. New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
8. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
9. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
10. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
11. PRA International Hosts Audio Conference on Site and Patient Recruitment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... , May 4, 2017  A recent ... Control, Ultraviolet-C light as a means ... SmartUVC,s ability to reduce bioburden on anesthesia workstations. ... reduction on high-touch, complex medical equipment surfaces contaminated ... infections. "This study further validates the ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... 22, 2017 , ... “Homeostasis: The Journey of a Manic-Depressive” tells the story ... Donald Rodriguez takes readers on a rollercoaster ride that includes a midnight trek to ... to a dark place where Donald considers suicide. Readers learn how Donald finally ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone ... Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor behavioral ... health education, all on their mobile phones. It also provides social networks for ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... pleased to announce the appointment of James (Jim) Vertino as Chief Information Officer ... a proven, transformational leader who drives innovation and business performance. He defines strategic ...
(Date:5/21/2017)... ... ... Pot. Reefer. Grass. Mary Jane. No matter what people call it, they ... before. More than a map, new social marketplace Weedable goes beyond providing ... for the first time – each other. A social marketplace like no other, Weedable ...
(Date:5/21/2017)... ... , ... For more than 20 years United Cutlery has been distinguished by ... from functional to fantasy. United Cutlery has always been “Stronger. Sharper” than the competition ... , Offering a range of weapons and tools built for battle, the M48 line ...
Breaking Medicine News(10 mins):